| Literature DB >> 26804566 |
Ruifang Wang1, Yongguo Yu1, Jun Ye1, Lianshu Han1, Wenjuan Qiu1, Huiwen Zhang1, Lili Liang1, Zhuwen Gong1, Lili Wang1, Xuefan Gu2.
Abstract
Steroid 21-hydroxylase deficiency (21-OHD) caused by the CYP21A2 gene mutations accounts for more than 90% of congenital adrenal hyperplasia (CAH) cases. In this study, molecular defects of 230 patients with 21-OHD were investigated. Point mutations of CYP21A2 gene were analyzed by Sanger sequencing, and large gene deletions were detected by multiplex ligation-dependent probe amplification (MLPA). Nine micro-conversions and 18 spontaneous mutations accounted for 74.6% of alleles, while large gene deletions and large gene conversions accounted for 25.4% of alleles. The most frequent micro-conversion was c.292-13A/C>G (I2G) (35%), followed by p.I173N (14.3%), p.R357W (5.9%) and p.Q319* (4.6%). Nine novel mutations were identified in these patients, which were predicted to hamper the 21-hydroxylase protein function in varying degrees. Genotype and phenotype correlated well in 89.6% of our patients, but disparity in phenotypic appearance also appeared in a small portion of the patients. 16.1% of the patients carried homozygous genotypes while 83.9% of patients carried compound heterozygous mutations. We concluded that the frequency of CYP21A2 mutations in our study was slightly different from those reported for other ethnic groups. Micro-conversions were the main category of the mutation spectrum, while large deletions and large gene conversions could also cause 21-OHD. A large portion of different types of the compound heterozygous genotypes may partially contribute to the discordance in genotype-phenotype comparison. This study expanded the CYP21A2 mutation spectrum of Chinese patients and could be helpful in prenatal diagnosis and genetic counseling for 21-OHD patients.Entities:
Keywords: 21-Hydroxylase deficiency; CYP21A2 gene; Congenital adrenal hyperplasia; Genotype–phenotype correlation; Mutational spectrum
Mesh:
Substances:
Year: 2016 PMID: 26804566 DOI: 10.1016/j.steroids.2016.01.007
Source DB: PubMed Journal: Steroids ISSN: 0039-128X Impact factor: 2.668